Results 41 to 50 of about 2,377 (150)

Siponimod to treat secondary progressive multiple sclerosis

, 2020
Siponimod fumarate (BAF-312) is a synthetic sphingosine 1- phosphate (S1P) receptor modulator, which exerts immunomodulating effects mediated by B- and T-cell sequestration in secondary lymphoid organs.
Gajofatto, A, Turatti, M, Turatti, M., Gajofatto, A.   +3 more
core   +1 more source

A Review of Biologically Active Oxime Ethers

Molecules, 2023
Oxime ethers are a class of compounds containing the >C=N-O-R moiety. The presence of this moiety affects the biological activity of the compounds. In this review, the structures of oxime ethers with specific biological activity have been collected and ...
Tomasz Kosmalski, Daria Kupczyk, Szymon Baumgart, Renata Paprocka, Renata Studzińska   +4 more
doaj   +1 more source

PSA analysis of siponimod compared with interferon beta-1b.

, 2022
PSA analysis of siponimod compared with interferon beta-1b.
Mihaela Nica (3357893), Lorenzo Giovanni Mantovani (8674071), Paolo Angelo Cortesi (4175632), Claudio Gasperini (349160), Ippazio Cosimo Antonazzo (3177453), Daniela Ritrovato (6874883)   +5 more
core   +1 more source

Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC)

Vaccines, 2023
Background: Evidence on SARS-CoV-2 mRNA vaccination under siponimod treatment is rare. Methods: AMA-VACC is a prospective, open-label clinical study on SARS-CoV-2 mRNA vaccination during ongoing siponimod treatment (cohort 1), during siponimod ...
Tjalf Ziemssen, Marie Groth, Veronika Eva Winkelmann, Tobias Bopp   +3 more
doaj   +1 more source

Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA

JMIR Research Protocols, 2020
BackgroundA high proportion of patients with relapsing remitting multiple sclerosis convert to secondary progressive multiple sclerosis (SPMS) characterized by irreversibly progressing disability and cognitive decline.
Ziemssen, Tjalf, Hoffmann, Olaf, Klotz, Luisa, Schreiber, Herbert, Weber, Martin S, Rauser, Benedict   +5 more
doaj   +1 more source

Single-Nucleus RNA-seq of Normal-Appearing Brain Regions in Relapsing-Remitting vs. Secondary Progressive Multiple Sclerosis: Implications for the Efficacy of Fingolimod

Frontiers in Cellular Neuroscience, 2022
Multiple sclerosis (MS) is an immune-mediated demyelinating disease that alters central nervous system (CNS) functions. Relapsing-remitting MS (RRMS) is the most common form, which can transform into secondary-progressive MS (SPMS) that is associated ...
Yasuyuki Kihara, Yunjiao Zhu, Deepa Jonnalagadda, William Romanow, Carter Palmer, Carter Palmer, Benjamin Siddoway, Richard Rivera, Ranjan Dutta, Bruce D. Trapp, Jerold Chun   +10 more
doaj   +1 more source

Siponimod ameliorates experimental autoimmune neuritis

Journal of Neuroinflammation, 2023
Background Guillain–Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are human autoimmune peripheral neuropathy. Besides humoral immunity, cellular immunity is also believed to contribute to these pathologies, especially ...
Takafumi Uchi, Shingo Konno, Hideo Kihara, Toshiki Fujioka   +3 more
doaj   +1 more source

Siponimod vs placebo in active secondary progressive multiple sclerosis

, 2022
\(\bf Background\) Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease ...
Fox, Robert J. (Dr. med.), Kappos, Ludwig (Prof. Dr. med.), Arnold, Douglas L. (Prof. Dr. med.), Benedict, Ralph H. B. (Dr.), Penner, Iris-Katharina (Prof. Dr. phil. Dipl.-Psych.), Dahlke, Frank (Dr.), Gold, Ralf (Prof. Dr. med.), Bar-Or, Amit (Prof. Dr.), Ritter, Shannon (M. Sc.), Hach, Thomas (Dr. med.), Piani-Meier, Daniela (Dr. rer. nat.), Giovannoni, Gavin (Prof. Dr.), Cree, Bruce A. C. (Prof. Dr. med.), Karlsson, Göril (Dr. rer. nat.), Vermersch, Patrick (Prof. Dr.), Kilaru, Ajay (Dr. med.), Rouyrre, Nicolas (M. Sc.)   +16 more
core   +1 more source

Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review

Bioengineering, 2023
Introduction. Cognitive impairment represents one of the most hidden and disabling clinical aspects of multiple sclerosis (MS). In this regard, the major challenges are represented by the need for a comprehensive and standardised cognitive evaluation of ...
Vincenzo Carlomagno, Massimiliano Mirabella, Matteo Lucchini   +2 more
doaj   +1 more source

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years [PDF]

, 2022
BACKGROUND: Siponimod significantly reduced the risk of confirmed disability progression (CDP), worsening in cognitive processing speed (CPS), relapses, and magnetic resonance imaging (MRI) measures of brain atrophy and inflammation versus placebo in ...
Fox, Robert J, Cree, Bruce AC, Bar-Or, Amit, Vermersch, Patrick, Rouyrre, Nicolas, Gold, Ralf, Benedict, Ralph HB, Ritter, Shannon, Kappos, Ludwig, Arnold, Douglas L, Kilaru, Ajay, Giovannoni, Gavin, Karlsson, Goeril, Piani-Meier, Daniela   +13 more
core   +1 more source